FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017611310> ?p ?o ?g. }

• W2017611310 abstract "Recombinant factor VIIa (rFVIIa) may be used for rapid hemostasis in life-threatening hemorrhage. In warfarin-associated intracerebral hemorrhage (wICH), FVIIa use is controversial and may carry significant thromboembolic risks. We compared incidence of baseline thromboembolic risk factors and thromboembolism rates in wICH patients treated with additional rFVIIa to those treated with standard therapy of fresh frozen plasma (FFP) and vitamin K alone.We identified 45 consecutive wICH patients treated with additional rFVIIa over 5-year period, and 34 consecutive wICH patients treated with standard therapy alone as comparison group. We compared the incidence of post-hemorrhage cardiac and extra-cardiac thromboembolic complications between two treatment groups, and used logistic regression to adjust for significant confounders such as baseline thromboembolic risk factors. We performed secondary analysis comparing the quantity of FFP transfused between two treatment cohorts.Both rFVIIa-treated and standard therapy-treated wICH patients had a high prevalence of pre-existing thromboembolic diseases including atrial fibrillation (73% vs 68%), deep venous thrombosis (DVT) or pulmonary embolism (PE) (22% vs 18%), coronary artery disease (CAD) (38% vs 32%), and abnormal electrocardiogram (EKG) (78% vs 85%). Troponin elevation following wICH was prevalent in both groups (47% vs 41%). Clinically significant myocardial infarction (MI), defined as troponin > 1.0 ng/dL, occurred in 13% of rFVIIa-treated and 6% of standard therapy-treated patients (p=0.52). Past history of CAD (p=0.0061) and baseline abnormal EKG (p=0.02) were independently associated with clinically significant MI following wICH while rFVIIa use was not. The incidences of DVT/PE (2% vs 9%; p=0.18) and ischemic stroke (2% vs 0%; p=0.38) were similar between two treatment groups. Recombinant FVIIa-treated patients had lower mean INR at 3 (p=0.0001) and 6 hours (p<0.0001) and received fewer units of FFP transfusion (3 vs 5; p=0.003).Pre-existing thromboembolic risk factors as well as post-hemorrhage troponin elevation are prevalent in wICH patients. Clinically significant MI occurs in up to 13% of wICH patients. rFVIIa use was not associated with increased incidence of clinically significant MI or other venous or arterial thromboembolic events in this wICH cohort." @default.
• W2017611310 created "2016-06-24" @default.
• W2017611310 creator A5003546898 @default.
• W2017611310 creator A5039961497 @default.
• W2017611310 creator A5051492792 @default.
• W2017611310 creator A5069804528 @default.
• W2017611310 creator A5073637960 @default.
• W2017611310 creator A5078939115 @default.
• W2017611310 creator A5085101582 @default.
• W2017611310 date "2012-12-01" @default.
• W2017611310 modified "2023-10-07" @default.
• W2017611310 title "Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study" @default.
• W2017611310 cites W1511722589 @default.
• W2017611310 cites W1965695013 @default.
• W2017611310 cites W1972516474 @default.
• W2017611310 cites W2017026770 @default.
• W2017611310 cites W2018067679 @default.
• W2017611310 cites W2020068593 @default.
• W2017611310 cites W2021556330 @default.
• W2017611310 cites W2022080618 @default.
• W2017611310 cites W2031759462 @default.
• W2017611310 cites W2031990245 @default.
• W2017611310 cites W2042961769 @default.
• W2017611310 cites W2047365101 @default.
• W2017611310 cites W2065683881 @default.
• W2017611310 cites W2074404195 @default.
• W2017611310 cites W2075238363 @default.
• W2017611310 cites W2088604835 @default.
• W2017611310 cites W2096698984 @default.
• W2017611310 cites W2096812386 @default.
• W2017611310 cites W2110167268 @default.
• W2017611310 cites W2115696894 @default.
• W2017611310 cites W2127079385 @default.
• W2017611310 cites W2139380855 @default.
• W2017611310 cites W2142640478 @default.
• W2017611310 cites W2143829405 @default.
• W2017611310 cites W2144129764 @default.
• W2017611310 cites W2152647843 @default.
• W2017611310 cites W2156589326 @default.
• W2017611310 cites W4239163935 @default.
• W2017611310 doi "https://doi.org/10.1186/1471-2377-12-158" @default.
• W2017611310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3538560" @default.
• W2017611310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23241423" @default.
• W2017611310 hasPublicationYear "2012" @default.
• W2017611310 type Work @default.
• W2017611310 sameAs 2017611310 @default.
• W2017611310 citedByCount "5" @default.
• W2017611310 countsByYear W20176113102014 @default.
• W2017611310 countsByYear W20176113102016 @default.
• W2017611310 countsByYear W20176113102017 @default.
• W2017611310 countsByYear W20176113102018 @default.
• W2017611310 countsByYear W20176113102022 @default.
• W2017611310 crossrefType "journal-article" @default.
• W2017611310 hasAuthorship W2017611310A5003546898 @default.
• W2017611310 hasAuthorship W2017611310A5039961497 @default.
• W2017611310 hasAuthorship W2017611310A5051492792 @default.
• W2017611310 hasAuthorship W2017611310A5069804528 @default.
• W2017611310 hasAuthorship W2017611310A5073637960 @default.
• W2017611310 hasAuthorship W2017611310A5078939115 @default.
• W2017611310 hasAuthorship W2017611310A5085101582 @default.
• W2017611310 hasBestOaLocation W20176113101 @default.
• W2017611310 hasConcept C120665830 @default.
• W2017611310 hasConcept C121332964 @default.
• W2017611310 hasConcept C126322002 @default.
• W2017611310 hasConcept C127413603 @default.
• W2017611310 hasConcept C141071460 @default.
• W2017611310 hasConcept C164705383 @default.
• W2017611310 hasConcept C2776265017 @default.
• W2017611310 hasConcept C2776301958 @default.
• W2017611310 hasConcept C2777094939 @default.
• W2017611310 hasConcept C2777736543 @default.
• W2017611310 hasConcept C2778213512 @default.
• W2017611310 hasConcept C2778961111 @default.
• W2017611310 hasConcept C2779161974 @default.
• W2017611310 hasConcept C2780645631 @default.
• W2017611310 hasConcept C2780868729 @default.
• W2017611310 hasConcept C42219234 @default.
• W2017611310 hasConcept C500558357 @default.
• W2017611310 hasConcept C61511704 @default.
• W2017611310 hasConcept C71924100 @default.
• W2017611310 hasConcept C78519656 @default.
• W2017611310 hasConceptScore W2017611310C120665830 @default.
• W2017611310 hasConceptScore W2017611310C121332964 @default.
• W2017611310 hasConceptScore W2017611310C126322002 @default.
• W2017611310 hasConceptScore W2017611310C127413603 @default.
• W2017611310 hasConceptScore W2017611310C141071460 @default.
• W2017611310 hasConceptScore W2017611310C164705383 @default.
• W2017611310 hasConceptScore W2017611310C2776265017 @default.
• W2017611310 hasConceptScore W2017611310C2776301958 @default.
• W2017611310 hasConceptScore W2017611310C2777094939 @default.
• W2017611310 hasConceptScore W2017611310C2777736543 @default.
• W2017611310 hasConceptScore W2017611310C2778213512 @default.
• W2017611310 hasConceptScore W2017611310C2778961111 @default.
• W2017611310 hasConceptScore W2017611310C2779161974 @default.
• W2017611310 hasConceptScore W2017611310C2780645631 @default.
• W2017611310 hasConceptScore W2017611310C2780868729 @default.
• W2017611310 hasConceptScore W2017611310C42219234 @default.
• W2017611310 hasConceptScore W2017611310C500558357 @default.
• W2017611310 hasConceptScore W2017611310C61511704 @default.
• W2017611310 hasConceptScore W2017611310C71924100 @default.

• next